![conference banner](/images/conference-banner.jpeg)
Abstract
Objective: Multiple lines of evidence indicate that pathological accumulation of amyloid
beta (Aβ) peptide in the brain is linked to the pathophysiology of Alzheimer’s disease (AD). Removal
of Aβ from the brain by binding to anti-Aβ specific antibodies is under active investigation. Vaccination
with a full-length Aβ42 peptide (AN1792) successfully elicited anti-Aβ antibodies in human subjects
with AD, but was associated with meningoencephalitis. To avoid this safety issue, an aminoterminal
Aβ
Keywords: Alzheimer’s disease, amyloid-beta, amyloid plaques, antibody, immunotherapy, vaccine.
Current Alzheimer Research
Title:Vanutide Cridificar and the QS-21 Adjuvant in Japanese Subjects with Mild to Moderate Alzheimer’ s Disease: Results from Two Phase 2 Studies
Volume: 12 Issue: 3
Author(s): Heii Arai, Hideo Suzuki and Tamotsu Yoshiyama
Affiliation:
Keywords: Alzheimer’s disease, amyloid-beta, amyloid plaques, antibody, immunotherapy, vaccine.
Abstract: Objective: Multiple lines of evidence indicate that pathological accumulation of amyloid
beta (Aβ) peptide in the brain is linked to the pathophysiology of Alzheimer’s disease (AD). Removal
of Aβ from the brain by binding to anti-Aβ specific antibodies is under active investigation. Vaccination
with a full-length Aβ42 peptide (AN1792) successfully elicited anti-Aβ antibodies in human subjects
with AD, but was associated with meningoencephalitis. To avoid this safety issue, an aminoterminal
Aβ
Export Options
About this article
Cite this article as:
Arai Heii, Suzuki Hideo and Yoshiyama Tamotsu, Vanutide Cridificar and the QS-21 Adjuvant in Japanese Subjects with Mild to Moderate Alzheimer’ s Disease: Results from Two Phase 2 Studies, Current Alzheimer Research 2015; 12 (3) . https://dx.doi.org/10.2174/1567205012666150302154121
DOI https://dx.doi.org/10.2174/1567205012666150302154121 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Innovative Methodology in the Discovery of Novel Drug Targets in the Free-Living Amoebae
Current Drug Targets The Role of Microglia in Antibody-Mediated Clearance of Amyloid-Beta from the Brain
CNS & Neurological Disorders - Drug Targets Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy
Current Topics in Medicinal Chemistry Immunopathology of Brucella Infection
Recent Patents on Anti-Infective Drug Discovery An Insight into Nanomedicinal Approaches to Combat Viral Zoonoses
Current Topics in Medicinal Chemistry Ginkgo Biloba Extract (EGb 761) in Alzheimers Disease: Is there Any Evidence?
Current Alzheimer Research Advances in Chagas Disease Chemotherapy
Anti-Infective Agents in Medicinal Chemistry Nucleic Acid Aptamers as Novel Class of Therapeutics to Mitigate Alzheimer’s Disease Pathology
Current Alzheimer Research Future Targeted Disease Modifying Drugs for Alzheimer's Disease
Recent Patents on CNS Drug Discovery (Discontinued) Intracellular Amyloid β-Protein As a Therapeutic Target for Treating Alzheimers Disease
Current Alzheimer Research Strategies to Diminish the Ab Load in Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab
Current Alzheimer Research Mitochondrial Calcium Signaling as a Therapeutic Target for Alzheimer’s Disease
Current Alzheimer Research Currently Used Biologic Agents in the Management of Behcet’s Syndrome
Current Medicinal Chemistry Borna Disease Virus (BDV): Neuropharmacological Effects of a CNS Viral Infection
Current Neuropharmacology Recent Updates on the Development of Therapeutics for the Targeted Treatment of Alzheimer’s Disease
Current Pharmaceutical Design Pharmacological Strategies for COVID-19 - A Review of the Most Promising Repurposed Antiviral Drugs
Infectious Disorders - Drug Targets Efficacy and Toxicity of Clioquinol Treatment and A-beta42 Inoculation in the APP/PSI Mouse Model of Alzheimer's Disease
Current Alzheimer Research The Functional Significance of Endocrine-immune Interactions in Health and Disease
Current Protein & Peptide Science Recombinant Antibody Fragments for Neurodegenerative Diseases
Current Neuropharmacology